Abstract:Introduction: We present a novel method to identify cancer driver genes that jointly examines any number of diverse transcriptomic alterations with the goal to uncover highly recurrent and heterogeneous patterns in 1190 samples across 26 cancer types as part of the PanCancer Analysis of Whole Genomes (PCAWG) of the International Cancer Genome Consortium (ICGC). Motivation: Previous pan-cancer genomic studies have focused on the analysis of somatic mutations as the driver of phenotypic changes. Here, we propose a method to integrate a wide variety of RNA and DNA changes to redefine the concept of driver events and account for the transcriptome’s role in tumorigenesis. PTK2 provides a motivating example, since it has many RNA alterations that correlate with patient survival, such as overexpression, exon-skips, and alternative promoter usage. In our analysis, we integrate an unprecedented amount of various alterations including gene fusions, RNA editing, alternative splicing, expression outliers, alternative promoters, allele specific expression, and somatic mutations. This enables us to also identify mutually exclusive (MutE) and co-occurring (CoO) patterns between different types of alterations within a gene. Methods: Our method has 3 main strengths: flexibility to handle any number or type of alteration, sensitivity to different frequencies of alterations so rare events are not lost in the recurrence analysis, and diversity of ranking such that genes with multiple alterations are prioritized. Our method is summarized in two steps: 1) Identify genes that are both recurrently and heterogeneously altered across many samples by calculating a rank-based score for each gene. 2) Identify MutE and CoO patterns between alteration types for the genes identified in the previous step. To ensure that alterations were comparable, we applied a thresholding model to binarize all alterations for gene-sample pairs, allowing us to account for the properties of the different modalities involved. Step 1 of our method calculates a score for each gene that takes into account: 1) the number of alterations to a gene across all samples, 2) the rarity of each alteration, and 3) how many types of alterations are observed per gene. The score is then used to rank the genes and top genes are considered for MutE and CoO analyses. Results: Our top 100 ranked genes were highly enriched for cancer census genes (adjusted p-value: 2.06e-9), indicating that we identify cancer relevant genes. Our top five ranked cancer census genes were IGF2, ERBB2, RARA, CREBBP, and ARID1A; all of which had at least 4 of 7 possible alterations, showing our scoring method prioritizes genes with diverse alterations. We also found that alternative promoter usage and alternative splicing were highly co-occurring alterations, with PTK2 having the highest co-occurrence between them. In summary, we propose a new method to analyze various RNA disruptions and show it can yield new insights beyond genomic variation. Citation Format: Natalie R. Davidson, PanCancer Analysis of Whole Genomes 3 (PCAWG-3) for ICGC, Alvis Brazma, Angela N. Brooks, Claudia Calabrese, Nuno A. Fonseca, Jonathan Goke, Yao He, Xueda Hu, Andre Kahles, Kjong-Van Lehmann, Fenglin Liu, Gunnar Ratsch, Siliang Li, Roland F. Schwarz, Mingyu Yang, Zemin Zhang, Fan Zhang, Liangtao Zheng. Integrating diverse transcriptomic alterations to identify cancer-relevant genes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 389. doi:10.1158/1538-7445.AM2017-389

Abstract 389: Integrating diverse transcriptomic alterations to identify cancer-relevant genes

Integrating Diverse Transcriptomic Alterations To Identify Cancer-Relevant Genes

Abstract 3971: DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies

Abstract SY10-02: Pan-cancer Study of Recurrent and Heterogeneous RNA Aberrations and Association with Whole-Genome Variants

Abstract 1253: Pan-cancer comparative and integrative analyses of driver alterations using Japanese and international genomic databases

Abstract 7346: Optimizing pan-cancer driver pathway analysis from patient transcriptomics and phosphoproteomics

DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies.

Abstract 360: Thousands of Published Cancer Signatures and Pathways Can Be Collapsed into a Handful of Non-Redundant Gene Programs: a TCGA Pan-Cancer Analysis

Abstract 4262: A pan-cancer proteomic analysis of The Cancer Genome Atlas (TCGA) project

Abstract 3437: Whole genome and transcriptome sequencing of a pan cancer cohort unearths novel therapeutic avenues

Integrating gene mutation spectra from tumors and the general population with gene expression topological networks to identify novel cancer driver genes

Pan-cancer study of heterogeneous RNA aberrations

Abstract 6915: Integrated proteogenomic analysis for the NCI patient-derived cancer model repository

Abstract 2214: an Integrative Approach to Reveal Driver Gene Fusions from Paired End Sequencing Data in Cancer

Abstract 1774: Examination of variants of unknown significance (VUSs) and co-occurring mutations from comprehensive genomic profiling (CGP) results in a cross tumor model

Cicero: An Accurate Method For Detecting Complex And Diverse Driver Fusions Using Cancer Transcriptome Sequencing (Rna-Seq) Data

Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.

Genomic basis for RNA alterations revealed by whole-genome analyses of 27 cancer types

Abstract 5073: Advancing precision oncology: Insights from pan-cancer proteogenomic signatures

Abstract 939: Comprehensive genomic and transcriptomic analysis to guide therapy for patients with metastatic solid tumors

Abstract 4885: Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer